On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early ...
Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy ...
AbbVie said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. "AbbVie's Tavapadon Hits Key Goals in Second Phase 3 ...
AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...
AbbVie has shared promising top-line results from a phase 3 study of its investigational Parkinson’s disease (PD) candidate tavapadon in adults and said it is “on track” to submit a new drug ...
NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible ...
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II ...
Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback